Vidofludimus
As of the edition of 20 October 2026, Vidofludimus is a small molecule: in active development; acts on DHODH.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 10, 1 stopped early
- Disease areas
- Immune system; Nervous system; Digestive system; Infections; Lungs and airways; Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| DHODH | Dihydroorotate dehydrogenase | Q02127 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 7 | 4 | 1 | 1 |
| Phase 3 | 3 | 1 | 2 | 0 |
| All trials | 10 |